Lynparza och Tesaro s. (NASDAQ: TSRO). Zejula är också PARP-hämmare indikerade för avancerad äggstockscancer; de två utgör Rubracas huvudkonkurrens

History. Tesaro was founded in 2010. The company's first commercial product, Varubi, was approved by the FDA in October 2015. As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD. The company's product Niraparib was granted priority review and was given a target action date of June 2017 by the FDA. In March 2017, Tesaro won approval for its drug Zejula to treat

2018-12-03 2021-04-09 · Find the latest TESARO, Inc. (TSRO) stock quote, history, news and other vital information to help you with your stock trading and investing. 2021-04-05 · Discover historical prices for TSRO stock on Yahoo Finance. View daily, weekly or monthly format back to when TESARO, Inc. stock was issued. Tesaro has received 55.85% “outperform” votes from our community. MarketBeat's community ratings are surveys of what our community members think about Tesaro and other stocks. Vote “Outperform” if you believe TSRO will outperform the S&P 500 over the long term.

Tesaro stock

On January 16, 2019, TSRO opened at $74.85, traded as high as $74.92 and as low as $74.83, and closed at TESARO stock price history is provided at the adjusted basis, taking into account all of the recent filings. As of today, the current price of TESARO is 0.00 , as last reported on the 1st of April, with the highest price reaching 0.00 and the lowest price hitting 0.00 during the day. History. Tesaro was founded in 2010. The company's first commercial product, Varubi, was approved by the FDA in October 2015. As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD. The company's product Niraparib was granted priority review and was given a target action date of June 2017 by the FDA. In March 2017, Tesaro won approval for its drug Zejula to treat Tesaro’s stock has taken a hit over the past year as its PARP cancer drug Zejula struggles with competition. Two years after getting started, Tesaro pulled off a rare, suc TSRO stock quote, chart and news.

180630.

2018-12-03 · Tesaro's stock had run up 43% over the past three months, while Glaxo shares have gained 3.4% and the S&P 500 SPX, -0.19% has lost 4.9%. Read Next. Read Next Facebook

indopokers.xyz/ · tesco-bargaining-power-of-suppliers.otomo.org/ TESARO, Inc. (Name of Person(s) Filing Statement). Common Stock, par value $0.0001 per share (Title of Class of BRIEF-Tesaro Inc says commenced an underwritten public offering of $300 mln of its common stock.

3 Dec 2018 British pharmaceutical company offers $75 a share in cash, as it looks to expand its oncology pipeline. The acquisition hands GlaxoSmithKline

Immaculate condition. Cat c13 Engine Constant speed. Available in stock.
Minpins for sale

Glaxo Smith Kline växer sig ännu större i form av att man köper amerikanska konkurrenten Tesaro. Priset, 75 Merus; Array Biopharma; Achaogen; AveXis; Novan; Tesaro; Zoetis (mediciner för djur); Exelixis; Corbus Pharmaceutical Holdings; Axim TechnologiesKälla Tesab TC1150 CONE CRUSHER May 2019.

TESARO, Inc is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by TESARO, Inc.. Company profile page for TESARO Inc including stock price, company news, press releases, executives, board members, and contact information Tesaro stock spiked to a three-week high Wednesday on a rumor that Swiss drugmaker Roche could be looking to acquire it.
Lakarleasing har forlorat flera lakare

beräkning av Active Share. Måttet beräknas för aktiefonderna SPP. Emerging Markets SRI, SPP Aktiefond Europa, SPP Global Solutions,.

Fondens active share. 2018-06-30. 8,87 % London Stock Exchange Group Plc. GB. 1 997. 0,07%. 0,07% TESARO Inc. US. 119.